RankAlpha logo
Back to Rankings

BCAX

Bicara TherapeuticsD
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
$10.02-$0.09 (-0.89%)
At close · 2026-11-13
View Chart

Operating peers and competitors

Source-backed product markets and frozen research comparisons. Valuation comparators remain in the existing peer table.

Loading market evidence...

Research comparisons do not establish forecast usefulness or trading returns.

Compare shared product markets

Membership only; no portfolio weights or estimated losses.

+
Peers tracked
10
U.S. public peers
Grade Position
In line
vs peer average
BCAX vs peer average
50/100
BCAX vs. peer average (D vs. D)
Grade spread
B 1 · C 1 · D 5 · F 3
Graded peers loaded
Coverage
10 graded
100% of tracked

Peer overview

GMAB is the first available peer comparator.

Genmab is a direct head-and-neck cancer competitive reference, not a valuation comparable: it reported positive Phase 3 petosemtamab results in first-line PD-L1-positive disease regardless of HPV status. Its larger, commercial-stage business limits multiple comparisons. [Genmab announcement](https://ir.genmab.com/news-releases/news-release-details/genmab-announces-statistically-significant-clinically-meaningful)

✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
Top peerGMABGenmab A/S
BCAX
Bicara Therapeutics
GMAB
Genmab A/S
Grade
D
D
Momentum
1
99
Value
41
61
Sentiment
80
11
Setup Bias
Net —
-
Market Cap
-
-
Posture
Defensive
Defensive
Open Side-by-Side ComparisonCompare top peers (up to 3)

Grade position vs GMAB

BCAX / GMAB
Grade Position
In line
BCAX vs. peer average (D vs. D)
50/100
Momentum
1
GMAB
Value
41
GMAB
Sentiment
80
BCAX

Rotation landscape

Peers ranked by the order returned from the peer source, with grades from the API.

Rank
Ticker
Company
Grade
Grade score
vs BCAX
1
GMAB
GMAB
D
40/100
Even
2
NBTX
NBTX
D
40/100
Even
3
CGEM
Cullinan Therapeutics Inc Common
B
80/100
+2
4
OLMA
Olema Oncology Inc Common
F
20/100
-1
5
DSGN
Design Therapeutics Inc Common
F
20/100
-1
GMAB is the first peer returned for this comparison set.